Clinical Application of Antibody-drug Conjugates Targeting Folate Receptor α(FRα)in Tumor Therapy
10.13865/j.cnki.cjbmb.2025.07.1114
- VernacularTitle:以叶酸受体α为靶点的抗体偶联药物在肿瘤治疗中的临床应用
- Author:
Shi-Ting YANG
1
;
Xue LIU
1
;
Wen-Xin LUO
1
Author Information
1. 厦门大学公共卫生学院 国家传染病诊断试剂与疫苗工程技术研究中心,福建厦门 361102
- Publication Type:Journal Article
- Keywords:
folate receptor α(FRα);
antibody-drug conjugates(ADC);
tumor therapy
- From:
Chinese Journal of Biochemistry and Molecular Biology
2025;41(11):1633-1644
- CountryChina
- Language:Chinese
-
Abstract:
Folate receptor α(FRα),encoded by the FOLR1 gene,is overexpressed in various solid tumors but minimally expressed in normal cells,making it a prime target for anti-tumor therapy.Antibod-y-drug conjugates(ADCs)can accurately deliver cytotoxic agents to tumor cells,enhancing treatment specificity and efficacy.Recent years have seen remarkable progress in the development of FRα-targeted ADCs,with multiple drugs entering clinical trials and demonstrating promising anti-tumor activity and safety.This review covers the latest clinical advances in FRα-targeted ADCs.It provides a detailed in-troduction to the structure and function of FRα,its expression in solid tumors,and the clinical progress of FRα-targeted ADCs.It particularly focuses on the clinical trials of drugs like Mirvetuximab Sor-avtansine,Luveltamab Tazevibulin,and Farletuzumab Ecteribulin.These drugs have shown significant anti-tumor effects in different cancer types,and Mirvetuximab Soravtansine has received FDA accelerated approval.Despite their potential,FRα ADCs face challenges in clinical applications,such as toxicity management,biomarker definition,and clinical translation.Future research should optimize FRα ADC design,including antibody selection,linker stability,and drug load efficiency,and explore their combi-nation with other therapies to enhance efficacy and broaden the therapeutic window.Additionally,in-depth studies on the role of FRα in the tumor microenvironment and its interaction with other signaling pathways will strengthen the theoretical basis for FRα ADC drug development.In summary,the develop-ment of FRα ADC drugs is rapidly advancing and is expected to offer new treatment options for FRα-posi-tive cancer patients.
